HOME
Leading the way to a cure

LUPUS NEWS

Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study

May 7, 2013

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced that additional data from its Phase 2b PEARL-SC study will be presented in two lecture sessions at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid, Spain.

Dr. Richard Furie, M.D., Chief of the Division of Rheumatology and Allergy-Clinical Immunology at the North Shore-Long Island Jewish Health System, will give two presentations summarizing the findings from the recently completed PEARL-SC Phase 2 trial with blisibimod in patients with SLE:

Novel Treatment in SLE and Sjögren's Syndrome (10:15-11:45 AM, June 13(th) ), "Effects of Blisibimod, a Subcutaneous Inhibitor of B-Cell Activating Factor, in Patients with SLE" New Drugs for Lupus: State of the Art (1:30-3:00 PM June 13(th) ), "Effects of Blisibimod, an Inhibitor of B-Cell Activating Factor, on Markers of Renal Disease in Patients with SLE."

***

Click here to read the full article.

Source: The Wall Street Journal


Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study

May 7, 2013

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced that additional data from its Phase 2b PEARL-SC study will be presented in two lecture sessions at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid, Spain.

Dr. Richard Furie, M.D., Chief of the Division of Rheumatology and Allergy-Clinical Immunology at the North Shore-Long Island Jewish Health System, will give two presentations summarizing the findings from the recently completed PEARL-SC Phase 2 trial with blisibimod in patients with SLE:

Novel Treatment in SLE and Sjögren's Syndrome (10:15-11:45 AM, June 13(th) ), "Effects of Blisibimod, a Subcutaneous Inhibitor of B-Cell Activating Factor, in Patients with SLE" New Drugs for Lupus: State of the Art (1:30-3:00 PM June 13(th) ), "Effects of Blisibimod, an Inhibitor of B-Cell Activating Factor, on Markers of Renal Disease in Patients with SLE."

***

Click here to read the full article.

Source: The Wall Street Journal



1.5 million

people in the U.S. have Lupus.

100 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software